COHANCE LIFESCIENCES LTD
Quality (43/100) does the heavy lifting; financial trend (0/100) is the drag.
ExpensiveOvervaluedOur blended model reads COHANCE LIFESCIENCES LTD as a Strong Sell at 24/100. At ₹440.2 it trades above our blended DCF and relative-multiples fair value of ₹285.31, about 35% downside to that estimate — we read it as overvalued by 35%. On 99.0x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 56% below its 52-week high of ₹990.7 and 57% above the low of ₹279.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹516.78 implies about 17% upside across 9 analysts. It clears 5 of 13 investability checks, with durability 43, valuation 29 and momentum 31 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹228.25.
Analyst views
1-year price
EOD · 2026-09-1452-week range
-55.57% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Sell24Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 3.8%
- Pass: Low debt (D/E < 0.5): 0.10x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -26%
- Fail: Earnings growing: -89%
- Fail: Net margin ≥ 10%: 7.9%
- Pass: Current ratio > 1.5: 2.83
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 7.31
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter64.0%
- Institutions25.5%
- Public & other10.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 7.31.
Opportunities
- Well off its 52-week high — possible mean-reversion.
Bear case
Weaknesses
- Low return on equity (3.8%).
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~35% above our estimated fair value.
About COHANCE LIFESCIENCES LTD
Cohance Lifesciences Limited provides contract research, development, and manufacturing services for new chemical entities, active pharmaceutical ingredients, specialty chemicals, and formulated drugs across India, the United States, Europe, and other markets. The company produces small molecule APIs, advanced intermediates, starting materials, antibody drug conjugates, and high-purity oligonucleotide building blocks including phosphoramidites and nucleosides.
COHANCE LIFESCIENCES LTD — frequently asked questions
Is COHANCE LIFESCIENCES LTD a buy, hold or sell?
StocksWizard currently rates COHANCE LIFESCIENCES LTD (COHANCE) a Strong Sell, based on a blended score of 24/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is COHANCE LIFESCIENCES LTD's fair value?
Our blended DCF and relative-valuation model estimates COHANCE LIFESCIENCES LTD's fair value at about ₹285.31, versus a current price of ₹440.2 — roughly 35% downside. On that basis the stock looks overvalued by 35%.
Is COHANCE LIFESCIENCES LTD financially healthy?
COHANCE LIFESCIENCES LTD scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has COHANCE LIFESCIENCES LTD's share price performed?
COHANCE LIFESCIENCES LTD is up 3% over three months, and last traded at ₹440.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.